NCT02471183 - Study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in Patients With Pulmonary Arterial Hypertension | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

October 12, 2015

Primary Completion Date

December 5, 2016

Study Completion Date

December 5, 2016

Conditions

Pulmonary Arterial Hypertension

Interventions

DRUG

Selexipag

Tablets for oral administration containing 200 micrograms (mcg) of selexipag to be administered twice a day. The individual dose is to be established during the first 12 weeks of the study. Doses are in the range from 200 micrograms (1 tablet) to 1,600 micrograms (8 tablets).

Trial Locations (15)

Unknown

UCSD Medical Center -La Jolla, La Jolla

UCSF Medical Center, San Francisco

Harbor UCLA Medical Center, Torrance

Emory University, Atlanta

Piedmont Healthcare Research Institute, Austell

Kentuckiana Pulmonary Associates, Louisville

University of Michigan Health System, Ann Arbor

Washington University School of Medicine, St Louis

Duke Unversity, Durham

University of Pennsylvania, Philadelphia

Allegheny General Hospital, Pittsburgh

University of Pittsburgh Medical Center Health System, Pittsburgh

UT Southwestern, Dallas

Houston Methodist Hospital, Houston

Sentara Cardiovascular Research Instistute, Norfolk